Based on preclinical experiments, using the malignant MCF7 line, Chen et al. 35 suggested that low SERPINA1 expression levels may be a strong indicator for bad response of ER+ and ER+/HER2+ breast tumors to anti-ER as well as anti-HER2 therapies. Here, ERBB2 is linked to breast neoplasm.